Analysts expect Blueprint Medicines Corporation (NASDAQ:BPMC) to post earnings per share of ($0.75) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Blueprint Medicines Corporation’s earnings. The highest EPS estimate is ($0.71) and the lowest is ($0.79). Blueprint Medicines Corporation reported earnings of ($0.70) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 7.1%. The firm is scheduled to issue its next earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Blueprint Medicines Corporation will report full year earnings of ($3.24) per share for the current year, with EPS estimates ranging from ($3.46) to ($3.14). For the next year, analysts anticipate that the company will post earnings of ($3.87) per share, with EPS estimates ranging from ($4.33) to ($3.59). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Blueprint Medicines Corporation.

Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.11. The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $6.02 million. Blueprint Medicines Corporation had a negative net margin of 317.57% and a negative return on equity of 55.58%. The firm’s quarterly revenue was down 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.57) earnings per share.

Several research analysts have weighed in on the company. Wedbush reiterated an “outperform” rating and set a $55.00 target price on shares of Blueprint Medicines Corporation in a report on Tuesday, June 6th. TheStreet downgraded Blueprint Medicines Corporation from a “c-” rating to a “d+” rating in a research note on Wednesday, May 3rd. Canaccord Genuity lifted their price target on Blueprint Medicines Corporation from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, April 4th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corporation in a research note on Tuesday, June 6th. Finally, Zacks Investment Research raised Blueprint Medicines Corporation from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Monday, March 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $47.40.

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its stake in Blueprint Medicines Corporation by 278.9% in the first quarter. Goldman Sachs Group Inc. now owns 353,556 shares of the biotechnology company’s stock worth $14,139,000 after buying an additional 260,247 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Blueprint Medicines Corporation during the first quarter worth about $4,119,000. Credit Suisse AG increased its stake in Blueprint Medicines Corporation by 27.6% in the first quarter. Credit Suisse AG now owns 40,045 shares of the biotechnology company’s stock worth $1,601,000 after buying an additional 8,650 shares in the last quarter. Tudor Investment Corp ET AL increased its stake in Blueprint Medicines Corporation by 8.0% in the first quarter. Tudor Investment Corp ET AL now owns 45,961 shares of the biotechnology company’s stock worth $1,838,000 after buying an additional 3,402 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its stake in Blueprint Medicines Corporation by 10.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 17,155 shares of the biotechnology company’s stock worth $686,000 after buying an additional 1,589 shares in the last quarter. 88.79% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Blueprint Medicines Corporation (BPMC) to Announce -$0.75 EPS” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/06/20/brokerages-anticipate-blueprint-medicines-corporation-bpmc-to-announce-0-75-eps.html.

Blueprint Medicines Corporation (NASDAQ BPMC) traded up 2.67% on Thursday, reaching $41.84. The company had a trading volume of 100,048 shares. The stock’s market capitalization is $1.39 billion. The firm has a 50 day moving average price of $39.53 and a 200-day moving average price of $36.80. Blueprint Medicines Corporation has a 12 month low of $17.35 and a 12 month high of $48.85.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines Corporation (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.